EMVision Medical Devices (ASX:EMV) swells 14% this week, taking five-year gains to 479%

EMVision Medical Devices Ltd (ASX:EMV) shareholders might be concerned after seeing the share price drop 14% in the last quarter. But that doesn’t change the fact that the returns over the last half decade have been spectacular. In fact, during that period, the share price climbed 479%. Impressive! So we don’t think the recent decline in the share price means its story is a sad one. The most important thing for savvy investors to consider is whether the underlying business can justify the share price gain.

The past week has proven to be lucrative for EMVision Medical Devices investors, so let’s see if fundamentals drove the company’s five-year performance.

Check out our latest analysis for EMVision Medical Devices

Given that EMVision Medical Devices didn’t make a profit in the last twelve months, we’ll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. That’s because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last 5 years EMVision Medical Devices saw its revenue grow at 41% per year. That’s well above most pre-profit companies. Fortunately, the market has not missed this, and has pushed the share price up by 42% per year in that time. It’s never too late to start following a top notch stock like EMVision Medical Devices, since some long term winners go on winning for decades. On the face of it, this looks like a good opportunity, although we note sentiment seems very positive already.

You can see below how earnings and revenue have changed over time (discover the exact values ​​by clicking on the image).

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphics.

A Different Perspective

It’s nice to see that EMVision Medical Devices shareholders have received a total shareholder return of 86% over the last year. That’s better than the annualized return of 42% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It’s always interesting to track share price performance over the longer term. But to understand EMVision Medical Devices better, we need to consider many other factors. Like risks, for instance. Every company has them, and we’ve spotted 2 warning signs for EMVision Medical Devices (of which 1 doesn’t sit too well with us!) you should know about.

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]